Recruiting

vMap & PVI

Sponsor:

Vektor Medical

Code:

NCT06935591

Conditions

Atrial Fibrillation (AF)

Eligibility Criteria

Sex: All

Age: 22+

Healthy Volunteers: Not accepted

Interventions

Pulmonary Vein Isolation

vMap® + Pulmonary Vein Isolation

Study Details

Brief summary:

The goal of this clinical trial is to compare the use of the Vektor Computational ECG Mapping System (vMap®) with pulmonary vein isolation (PVI), to using PVI alone, to treat Atrial Fibrillation (AF) in adults.

Participants will have a 50/50 or 1 out of 2 chance of being placed in the treatment or control arm. The control arm of the study involves PVI alone for ablation procedure(s). The treatment arm involves the use of vMap mapping in addition to PVI to plan ablation procedure(s).

Conditions

Atrial Fibrillation (AF)

Study ID

NCT06935591

Start date

Jun 27, 2025

Status verified date

Mar, 2026

Completion date

Dec, 2027

Anticipated

Primary completion date

Oct, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 22+

Healthy Volunteers: Not accepted

Inclusion Criteria:

1. Subjects diagnosed with persistent (not longstanding) AF or recurrent AF, as defined for this study.
2. Subject has a recent 12-lead electrogram data of AF (including baseline, pacing and clinical arrhythmia) recorded on the electrogram recording system (e.g., Bard, Boston-Scientific, St. Paul, MN or Prucka, GE Medical) or standalone ECG system (e.g., GE Muse, Minnesota, or CardioCard (Nasiff, NY) in digitized format.
3. The following data elements can be abstracted from the patient medical records or confirmed and documented prior to the scheduled procedure (to be inputted in vMap®):

  • Atrial fibrillation type
  • Atrial characteristics: geometry (normal, left and/or right atrial enlargement), Utah classification, prior ablation modality (e.g., radiofrequency, cryoablation, pulsed field ablation), prior ablation lesion location(s).
4. Subject is ≥ 22 years of age at time of enrollment/consent.
5. Subject is indicated to undergo an ablation procedure at the medical discretion of the Investigator.
6. Subject is able and willing to comply with the protocol requirements, has been informed of the nature of the study,

Exclusion Criteria:

1. Subjects with arrhythmias other than persistent or recurring AF as defined for this study, including long-standing persistent atrial fibrillation (persistent AF lasting ≥ 1 year from diagnosis).
2. Inability to obtain ECG prior to or during the clinical ablation procedure; or unacceptable ECG data quality such as low ECG signal-to-noise ratio or lack of ECG data in one or more leads.
3. Subjects who are participating in another clinical investigation with an investigational drug or device at the time of enrollment or planned participation at any time during this clinical investigation.
4. Subjects who have a known or suspected medical condition that, in the opinion of the Investigator, may put the subject at risk for participation in this clinical investigation.
5. Subjects who are pregnant as confirmed by the institution's standard pre-surgery practice.
6. Subject has had prior PVI and all four pulmonary veins are confirmed to be isolated based on voltage readings during the study index procedure.

Study Design

Enrollment

423 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: vMap®+PVI

Subjects in this arm will be treated with the use of the vMap® system in addition to pulmonary vein isolation.

active comparator: PVI Alone

Subjects in this arm will be treated with pulmonary vein isolation alone.

Interventions

Pulmonary Vein Isolation

Subjects will receive treatment for Atrial Fibrillation with Pulmonary Vein Isolation per standard of care.

vMap® + Pulmonary Vein Isolation

Subjects will receive treatment for Atrial Fibrillation with the use of the vMap® system and Pulmonary Vein Isolation.

Primary outcome measure

  • Freedom from AF [ Time Frame: 12 months post procedure ]

Central Contacts and Locations

Locations

Arrhythmia Research Group - St. Bernards

Recruiting

Jonesboro, Arkansas, United States, 72401

Contacts

Principal Investigator:

Devi Nair, MD

BayCare Health System

Recruiting

Clearwater, Florida, United States, 33759

Contacts

Principal Investigator:

Vaibhav Moondra, MD

Baptist Health Jacksonville

Recruiting

Jacksonville, Florida, United States, 32207

Contacts

Principal Investigator:

Matthew S McKillop, MD

USF Health

Recruiting

Tampa, Florida, United States, 33606

Contacts

Executive Director, Clinical Operations

813-974-3823karlnosk@usf.edu

Principal Investigator:

David Wilson, MD

Piedmont Heart Institute

Recruiting

Atlanta, Georgia, United States, 30309

Contacts

Principal Investigator:

Sandeep Goyal, MD

Indiana University

Recruiting

Indianapolis, Indiana, United States, 46202

Contacts

Principal Investigator:

Mithilesh Das, MD

Baptist Health Lexignton

Recruiting

Lexington, Kentucky, United States, 40503

Contacts

Principal Investigator:

Gery Tomassoni, MD

Westchester Medical Center

Recruiting

Valhalla, New York, United States, 10595

Contacts

Principal Investigator:

Sei Iwai, MD

OhioHealth

Recruiting

Columbus, Ohio, United States, 43202

Contacts

Principal Investigator:

Anish Amin, MD

Penn Presbyterian

Recruiting

Philadelphia, Pennsylvania, United States, 19104-4238

Contacts

Principal Investigator:

Benjamin D'Souza, MD

More Information

Sponsor

Vektor Medical

Last update posted

Mar 16, 2026

Last verified

Mar, 2026

Keywords

  • Atrial Fibrillation
  • Pulmonary Vein Isolation
  • Ablation

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-08. This information was provided to ClinicalTrials.gov by Vektor Medical on 2026-03-16.